Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 77770, held by Padagis Israel. Desoximetasone.
As of Nov 15, 2026, ANDA 77770 (Desoximetasone), held by Padagis Israel, was first approved by FDA on Apr 20, 2015, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Desoximetasone Ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 20, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · ointment;topical | Desoximetasone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
